ES2091824T3 - Proteina recombinante de fusion toxina anticuerpo. - Google Patents
Proteina recombinante de fusion toxina anticuerpo.Info
- Publication number
- ES2091824T3 ES2091824T3 ES90907767T ES90907767T ES2091824T3 ES 2091824 T3 ES2091824 T3 ES 2091824T3 ES 90907767 T ES90907767 T ES 90907767T ES 90907767 T ES90907767 T ES 90907767T ES 2091824 T3 ES2091824 T3 ES 2091824T3
- Authority
- ES
- Spain
- Prior art keywords
- fusion protein
- recombinant fusion
- protein antibody
- antibody toxin
- toxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003053 toxin Substances 0.000 title abstract 4
- 231100000765 toxin Toxicity 0.000 title abstract 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 238000010276 construction Methods 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108700012359 toxins Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Abstract
LA INVENCION DESCRIBE PROTEINAS DE FUSION ANTICUERPO-TOXINA RECOMBINANTES QUE MATAN DE MANERA SELECTIVA CELULAS QUE LLEVAN ANTIGENOS O RECEPTORES APROPIADOS. SE DESCRIBEN LA CONSTRUCCION Y EXPRESION DE UNA PROTEINA DE FUSION ANTICUERPO-TOXINA DE CADENA SENCILLA, ANTI-TAC(FV)-PE40, GEN Y CON ESTO LA PRODUCCION DE TOXINAS MEJORADAS UTILIZANDO PE.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34136189A | 1989-04-21 | 1989-04-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2091824T3 true ES2091824T3 (es) | 1996-11-16 |
Family
ID=23337235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES90907767T Expired - Lifetime ES2091824T3 (es) | 1989-04-21 | 1990-04-20 | Proteina recombinante de fusion toxina anticuerpo. |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0469065B1 (es) |
JP (1) | JPH0829101B2 (es) |
AT (1) | ATE138688T1 (es) |
AU (1) | AU641392B2 (es) |
CA (1) | CA2053911C (es) |
DE (1) | DE69027210T2 (es) |
DK (1) | DK0469065T3 (es) |
ES (1) | ES2091824T3 (es) |
IL (1) | IL94159A0 (es) |
WO (1) | WO1990012592A1 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU631200B2 (en) * | 1989-02-17 | 1992-11-19 | Merck & Co., Inc. | Production of modified pe40 |
DK0383599T3 (da) * | 1989-02-17 | 1996-08-05 | Merck & Co Inc | Protein-anticancermiddel |
US6099842A (en) * | 1990-12-03 | 2000-08-08 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin |
US5571894A (en) * | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
US5939531A (en) * | 1991-07-15 | 1999-08-17 | Novartis Corp. | Recombinant antibodies specific for a growth factor receptor |
JP3512795B2 (ja) * | 1991-09-30 | 2004-03-31 | アメリカ合衆国 | 組換免疫毒素 |
JP3024311B2 (ja) | 1991-10-03 | 2000-03-21 | 味の素株式会社 | Il−2受容体重鎖に結合するポリペプチド |
US6146850A (en) * | 1991-11-04 | 2000-11-14 | Xoma Corporation | Proteins encoding gelonin sequences |
US5621083A (en) | 1991-11-04 | 1997-04-15 | Xoma Corporation | Immunotoxins comprising ribosome-inactivating proteins |
US5837491A (en) * | 1991-11-04 | 1998-11-17 | Xoma Corporation | Polynucleotides encoding gelonin sequences |
EP1997894B1 (en) * | 1992-02-06 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
AU7394296A (en) * | 1995-10-19 | 1997-05-07 | Bristol-Myers Squibb Company | Monoclonal antibody br110 and uses thereof |
IL116559A (en) * | 1995-11-17 | 2005-11-20 | Yissum Res Dev Co | Chimeric protein consisting of a bacterial toxin and a myelin basic protein sequence |
IL116436A (en) | 1995-12-18 | 2006-12-31 | Yissum Res Dev Co | Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND |
WO1998017116A1 (en) * | 1996-10-23 | 1998-04-30 | Wake Forest University | Targeted cytotoxic cells |
DK2631248T3 (en) | 2007-06-15 | 2018-02-12 | Medigene Ag | Treatment of tumors using specific anti-L1 antibody |
US8932586B2 (en) | 2011-09-06 | 2015-01-13 | Intrexon Corporation | Modified forms of Pseudomonas exotoxin A |
US10400037B2 (en) | 2014-09-30 | 2019-09-03 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Binding molecules, especially antibodies, binding to L1CAM (CD171) |
WO2016146833A1 (en) | 2015-03-19 | 2016-09-22 | F. Hoffmann-La Roche Ag | Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance |
EP3184547A1 (en) | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
BR112019013107A2 (pt) | 2016-12-22 | 2019-12-17 | Univ Degli Studi Magna Graecia Catanzaro | anticorpos, molécula de ligação, receptor de antígeno quimérico, vetor de expressão, composição farmacêutica, linfócito, ácido nucleico, célula de hibridoma, método para a produção do anticorpo monoclonal e usos |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0108146B1 (en) * | 1982-05-12 | 1987-01-28 | The President And Fellows Of Harvard College | Fused genes encoding hybrid proteins, cloning vectors containing them and the use thereof |
US4545985A (en) * | 1984-01-26 | 1985-10-08 | The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services | Pseudomonas exotoxin conjugate immunotoxins |
US4894443A (en) * | 1984-02-08 | 1990-01-16 | Cetus Corporation | Toxin conjugates |
US4892827A (en) * | 1986-09-24 | 1990-01-09 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects |
US4867962A (en) * | 1988-02-26 | 1989-09-19 | Neorx Corporation | Functionally specific antibodies |
DK0383599T3 (da) * | 1989-02-17 | 1996-08-05 | Merck & Co Inc | Protein-anticancermiddel |
-
1990
- 1990-04-20 AU AU55627/90A patent/AU641392B2/en not_active Expired
- 1990-04-20 ES ES90907767T patent/ES2091824T3/es not_active Expired - Lifetime
- 1990-04-20 CA CA002053911A patent/CA2053911C/en not_active Expired - Lifetime
- 1990-04-20 WO PCT/US1990/002097 patent/WO1990012592A1/en active IP Right Grant
- 1990-04-20 DE DE69027210T patent/DE69027210T2/de not_active Expired - Lifetime
- 1990-04-20 DK DK90907767.9T patent/DK0469065T3/da active
- 1990-04-20 JP JP2507079A patent/JPH0829101B2/ja not_active Expired - Fee Related
- 1990-04-20 EP EP90907767A patent/EP0469065B1/en not_active Expired - Lifetime
- 1990-04-20 AT AT90907767T patent/ATE138688T1/de not_active IP Right Cessation
- 1990-04-22 IL IL94159A patent/IL94159A0/xx unknown
Also Published As
Publication number | Publication date |
---|---|
DE69027210D1 (de) | 1996-07-04 |
JPH0829101B2 (ja) | 1996-03-27 |
DE69027210T2 (de) | 1997-01-23 |
WO1990012592A1 (en) | 1990-11-01 |
CA2053911C (en) | 1999-11-02 |
IL94159A0 (en) | 1991-01-31 |
ATE138688T1 (de) | 1996-06-15 |
AU5562790A (en) | 1990-11-16 |
EP0469065B1 (en) | 1996-05-29 |
AU641392B2 (en) | 1993-09-23 |
EP0469065A1 (en) | 1992-02-05 |
CA2053911A1 (en) | 1990-10-22 |
JPH04504363A (ja) | 1992-08-06 |
EP0469065A4 (en) | 1992-07-08 |
DK0469065T3 (da) | 1996-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2091824T3 (es) | Proteina recombinante de fusion toxina anticuerpo. | |
CY1117756T1 (el) | Χιμαιρικα υβριδια μονομερους-διμερους ανοσοσφαιρινης | |
IT8367525A0 (it) | Proteina ibrida comprendente frammenti proteici collegati da legami peptidici e relativo gene di fusione composizione contenente tale proteina | |
ES2129487T3 (es) | Peptidos sinteticos, anticuerpos dirigidos contra ellos y su utilizacion. | |
ATE329033T1 (de) | Hybride toxine | |
BR9507594B8 (pt) | Anticorpo monoclonal com scfv humanizado, molécula de ácido nucleico recombinante e proteína recombinante. | |
DE59708952D1 (de) | Fusionspolypeptid zur beeinflussung von wechselwirkungen zwischen proteinen | |
DE69228701D1 (de) | Fragmente von Prion Proteinen. | |
NO885326L (no) | Human vevfaktor-beslektede dna-segmenter, polypeptider ogantistoffer. | |
TR199902878T2 (xx) | Tip II TGF-Beta Resept�r/�m�noglob�lin sabit b�l�m f�zyon proteinleri. | |
DK1140173T3 (da) | Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf | |
ES2304795T3 (es) | Anticuerpos agonistas para el receptor de trombopoyetina y sus usos terapeuticos. | |
DK1887014T3 (da) | Humane Toll-homologer | |
ES557188A0 (es) | Un metodo para obtener un polipeptido complementario de al menos una porcion de un peptido o proteina original | |
DE3586456T2 (de) | Hybrides protein. | |
BR9509172A (pt) | Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéutica | |
ES2042461T1 (es) | Producto y procedimiento para el te\ido oxidativo del cabello. | |
PT625157E (pt) | Epitopes p1a1 e p1a2 da gpiiia da plaqueta sua preparacao e utilizacao | |
DE59608073D1 (de) | Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid | |
DE69333111D1 (de) | Natürliche menschliche igm antikörper | |
FI974018A0 (fi) | Ihmisen 2 integriini -alayksikkö | |
ES2067501T3 (es) | Antigeno recombinante de treponema hyodysenteriae y sus usos. | |
ES2107545T3 (es) | Anticuerpos policlonales dirigidos contra la hirudina y su utilizacion para la identificacion, la purificacion inmunologica y la determinacion cuantitativa de la hirudina. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 469065 Country of ref document: ES |